{"id":108917,"date":"2021-05-27T11:00:34","date_gmt":"2021-05-27T11:00:34","guid":{"rendered":"https:\/\/www.healthbenefitstimes.com\/glossary\/?p=108917"},"modified":"2022-09-07T05:56:04","modified_gmt":"2022-09-07T05:56:04","slug":"metachromatic-leukodystrophy","status":"publish","type":"post","link":"https:\/\/www.healthbenefitstimes.com\/glossary\/metachromatic-leukodystrophy\/","title":{"rendered":"Metachromatic leukodystrophy"},"content":{"rendered":"<p>Metachromatic leukodystrophy (MLD) is the most common subgroup of the leukodystrophies, a group of disorders that affects the white matter or myelin sheath. MLD is associated with the accumulation of cerebroside sulfates, a group of myelin lipids (fats); it leads to staining (metachromasia) of brain and other nervous tissue that does not occur in other leukodystrophies. MLDs are genetic and generally marked by the absence or near-absence of the enzyme arylsulfatase A.<\/p>\n<hr \/>\n<p>A type of hereditary leukodystrophy caused by a deficiency of the enzyme cerebroside sulfatase, an enzyme that is essential for the degradation of sulfatide. Deficiency of the enzyme allows excess deposition of sulfatide in nerve tissues. Clinical signs of this disease usually appear at about 1 year of age. They include gait disturbance, inability to learn to walk, spasticity of the limbs, hyperreflexia, dementia, and eventually death. The disease, for which there is no specific therapy, is usually fatal by age 10.<\/p>\n<hr \/>\n<p>&nbsp;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Metachromatic leukodystrophy (MLD) is the most common subgroup of the leukodystrophies, a group of disorders that affects the white matter or myelin sheath. MLD is associated with the accumulation of cerebroside sulfates, a group of myelin lipids (fats); it leads to staining (metachromasia) of brain and other nervous tissue that does not occur in other [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":["post-108917","post","type-post","status-publish","format-standard","hentry","category-m"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v21.1 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Metachromatic leukodystrophy - Definition of Metachromatic leukodystrophy<\/title>\n<meta name=\"description\" content=\"Metachromatic leukodystrophy (MLD) is the most common subgroup of the leukodystrophies, a group of disorders that affects the white matter or myelin sheath. MLD is associated with the accumulation of cerebroside sulfates, a group of myelin lipids (fats); it leads to staining (metachromasia) of brain and other nervous tissue that does not occur in other leukodystrophies. MLDs are genetic and generally marked by the absence or near-absence of the enzyme arylsulfatase A.A type of hereditary leukodystrophy caused by a deficiency of the enzyme cerebroside sulfatase, an enzyme that is essential for the degradation of sulfatide. Deficiency of the enzyme allows excess deposition of sulfatide in nerve tissues. Clinical signs of this disease usually appear at about 1 year of age. They include gait disturbance, inability to learn to walk, spasticity of the limbs, hyperreflexia, dementia, and eventually death. The disease, for which there is no specific therapy, is usually fatal by age 10.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.healthbenefitstimes.com\/glossary\/metachromatic-leukodystrophy\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Metachromatic leukodystrophy - Definition of Metachromatic leukodystrophy\" \/>\n<meta property=\"og:description\" content=\"Metachromatic leukodystrophy (MLD) is the most common subgroup of the leukodystrophies, a group of disorders that affects the white matter or myelin sheath. MLD is associated with the accumulation of cerebroside sulfates, a group of myelin lipids (fats); it leads to staining (metachromasia) of brain and other nervous tissue that does not occur in other leukodystrophies. MLDs are genetic and generally marked by the absence or near-absence of the enzyme arylsulfatase A.A type of hereditary leukodystrophy caused by a deficiency of the enzyme cerebroside sulfatase, an enzyme that is essential for the degradation of sulfatide. Deficiency of the enzyme allows excess deposition of sulfatide in nerve tissues. Clinical signs of this disease usually appear at about 1 year of age. They include gait disturbance, inability to learn to walk, spasticity of the limbs, hyperreflexia, dementia, and eventually death. The disease, for which there is no specific therapy, is usually fatal by age 10.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.healthbenefitstimes.com\/glossary\/metachromatic-leukodystrophy\/\" \/>\n<meta property=\"og:site_name\" content=\"Glossary\" \/>\n<meta property=\"article:published_time\" content=\"2021-05-27T11:00:34+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2022-09-07T05:56:04+00:00\" \/>\n<meta name=\"author\" content=\"Glossary\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Glossary\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.healthbenefitstimes.com\/glossary\/metachromatic-leukodystrophy\/\",\"url\":\"https:\/\/www.healthbenefitstimes.com\/glossary\/metachromatic-leukodystrophy\/\",\"name\":\"Metachromatic leukodystrophy - Definition of Metachromatic leukodystrophy\",\"isPartOf\":{\"@id\":\"https:\/\/www.healthbenefitstimes.com\/glossary\/#website\"},\"datePublished\":\"2021-05-27T11:00:34+00:00\",\"dateModified\":\"2022-09-07T05:56:04+00:00\",\"author\":{\"@id\":\"https:\/\/www.healthbenefitstimes.com\/glossary\/#\/schema\/person\/ccfef987a4882e6356ae6d77d33e74c5\"},\"description\":\"Metachromatic leukodystrophy (MLD) is the most common subgroup of the leukodystrophies, a group of disorders that affects the white matter or myelin sheath. MLD is associated with the accumulation of cerebroside sulfates, a group of myelin lipids (fats); it leads to staining (metachromasia) of brain and other nervous tissue that does not occur in other leukodystrophies. MLDs are genetic and generally marked by the absence or near-absence of the enzyme arylsulfatase A.A type of hereditary leukodystrophy caused by a deficiency of the enzyme cerebroside sulfatase, an enzyme that is essential for the degradation of sulfatide. Deficiency of the enzyme allows excess deposition of sulfatide in nerve tissues. Clinical signs of this disease usually appear at about 1 year of age. They include gait disturbance, inability to learn to walk, spasticity of the limbs, hyperreflexia, dementia, and eventually death. The disease, for which there is no specific therapy, is usually fatal by age 10.\",\"breadcrumb\":{\"@id\":\"https:\/\/www.healthbenefitstimes.com\/glossary\/metachromatic-leukodystrophy\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.healthbenefitstimes.com\/glossary\/metachromatic-leukodystrophy\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.healthbenefitstimes.com\/glossary\/metachromatic-leukodystrophy\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.healthbenefitstimes.com\/glossary\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Metachromatic leukodystrophy\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.healthbenefitstimes.com\/glossary\/#website\",\"url\":\"https:\/\/www.healthbenefitstimes.com\/glossary\/\",\"name\":\"Glossary\",\"description\":\"Difinitions\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.healthbenefitstimes.com\/glossary\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.healthbenefitstimes.com\/glossary\/#\/schema\/person\/ccfef987a4882e6356ae6d77d33e74c5\",\"name\":\"Glossary\",\"url\":\"https:\/\/www.healthbenefitstimes.com\/glossary\/author\/adminglossary\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Metachromatic leukodystrophy - Definition of Metachromatic leukodystrophy","description":"Metachromatic leukodystrophy (MLD) is the most common subgroup of the leukodystrophies, a group of disorders that affects the white matter or myelin sheath. MLD is associated with the accumulation of cerebroside sulfates, a group of myelin lipids (fats); it leads to staining (metachromasia) of brain and other nervous tissue that does not occur in other leukodystrophies. MLDs are genetic and generally marked by the absence or near-absence of the enzyme arylsulfatase A.A type of hereditary leukodystrophy caused by a deficiency of the enzyme cerebroside sulfatase, an enzyme that is essential for the degradation of sulfatide. Deficiency of the enzyme allows excess deposition of sulfatide in nerve tissues. Clinical signs of this disease usually appear at about 1 year of age. They include gait disturbance, inability to learn to walk, spasticity of the limbs, hyperreflexia, dementia, and eventually death. The disease, for which there is no specific therapy, is usually fatal by age 10.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.healthbenefitstimes.com\/glossary\/metachromatic-leukodystrophy\/","og_locale":"en_US","og_type":"article","og_title":"Metachromatic leukodystrophy - Definition of Metachromatic leukodystrophy","og_description":"Metachromatic leukodystrophy (MLD) is the most common subgroup of the leukodystrophies, a group of disorders that affects the white matter or myelin sheath. MLD is associated with the accumulation of cerebroside sulfates, a group of myelin lipids (fats); it leads to staining (metachromasia) of brain and other nervous tissue that does not occur in other leukodystrophies. MLDs are genetic and generally marked by the absence or near-absence of the enzyme arylsulfatase A.A type of hereditary leukodystrophy caused by a deficiency of the enzyme cerebroside sulfatase, an enzyme that is essential for the degradation of sulfatide. Deficiency of the enzyme allows excess deposition of sulfatide in nerve tissues. Clinical signs of this disease usually appear at about 1 year of age. They include gait disturbance, inability to learn to walk, spasticity of the limbs, hyperreflexia, dementia, and eventually death. The disease, for which there is no specific therapy, is usually fatal by age 10.","og_url":"https:\/\/www.healthbenefitstimes.com\/glossary\/metachromatic-leukodystrophy\/","og_site_name":"Glossary","article_published_time":"2021-05-27T11:00:34+00:00","article_modified_time":"2022-09-07T05:56:04+00:00","author":"Glossary","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Glossary","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.healthbenefitstimes.com\/glossary\/metachromatic-leukodystrophy\/","url":"https:\/\/www.healthbenefitstimes.com\/glossary\/metachromatic-leukodystrophy\/","name":"Metachromatic leukodystrophy - Definition of Metachromatic leukodystrophy","isPartOf":{"@id":"https:\/\/www.healthbenefitstimes.com\/glossary\/#website"},"datePublished":"2021-05-27T11:00:34+00:00","dateModified":"2022-09-07T05:56:04+00:00","author":{"@id":"https:\/\/www.healthbenefitstimes.com\/glossary\/#\/schema\/person\/ccfef987a4882e6356ae6d77d33e74c5"},"description":"Metachromatic leukodystrophy (MLD) is the most common subgroup of the leukodystrophies, a group of disorders that affects the white matter or myelin sheath. MLD is associated with the accumulation of cerebroside sulfates, a group of myelin lipids (fats); it leads to staining (metachromasia) of brain and other nervous tissue that does not occur in other leukodystrophies. MLDs are genetic and generally marked by the absence or near-absence of the enzyme arylsulfatase A.A type of hereditary leukodystrophy caused by a deficiency of the enzyme cerebroside sulfatase, an enzyme that is essential for the degradation of sulfatide. Deficiency of the enzyme allows excess deposition of sulfatide in nerve tissues. Clinical signs of this disease usually appear at about 1 year of age. They include gait disturbance, inability to learn to walk, spasticity of the limbs, hyperreflexia, dementia, and eventually death. The disease, for which there is no specific therapy, is usually fatal by age 10.","breadcrumb":{"@id":"https:\/\/www.healthbenefitstimes.com\/glossary\/metachromatic-leukodystrophy\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.healthbenefitstimes.com\/glossary\/metachromatic-leukodystrophy\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.healthbenefitstimes.com\/glossary\/metachromatic-leukodystrophy\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.healthbenefitstimes.com\/glossary\/"},{"@type":"ListItem","position":2,"name":"Metachromatic leukodystrophy"}]},{"@type":"WebSite","@id":"https:\/\/www.healthbenefitstimes.com\/glossary\/#website","url":"https:\/\/www.healthbenefitstimes.com\/glossary\/","name":"Glossary","description":"Difinitions","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.healthbenefitstimes.com\/glossary\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.healthbenefitstimes.com\/glossary\/#\/schema\/person\/ccfef987a4882e6356ae6d77d33e74c5","name":"Glossary","url":"https:\/\/www.healthbenefitstimes.com\/glossary\/author\/adminglossary\/"}]}},"_links":{"self":[{"href":"https:\/\/www.healthbenefitstimes.com\/glossary\/wp-json\/wp\/v2\/posts\/108917","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.healthbenefitstimes.com\/glossary\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.healthbenefitstimes.com\/glossary\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.healthbenefitstimes.com\/glossary\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.healthbenefitstimes.com\/glossary\/wp-json\/wp\/v2\/comments?post=108917"}],"version-history":[{"count":2,"href":"https:\/\/www.healthbenefitstimes.com\/glossary\/wp-json\/wp\/v2\/posts\/108917\/revisions"}],"predecessor-version":[{"id":180910,"href":"https:\/\/www.healthbenefitstimes.com\/glossary\/wp-json\/wp\/v2\/posts\/108917\/revisions\/180910"}],"wp:attachment":[{"href":"https:\/\/www.healthbenefitstimes.com\/glossary\/wp-json\/wp\/v2\/media?parent=108917"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.healthbenefitstimes.com\/glossary\/wp-json\/wp\/v2\/categories?post=108917"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.healthbenefitstimes.com\/glossary\/wp-json\/wp\/v2\/tags?post=108917"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}